<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03680612</url>
  </required_header>
  <id_info>
    <org_study_id>AT-201</org_study_id>
    <nct_id>NCT03680612</nct_id>
  </id_info>
  <brief_title>Cefepime/AAI101 Phase 2 Study in Hospitalized Adults With cUTI</brief_title>
  <official_title>Randomized, Double-Blind, Multi-Center Study of Cefepime/AAI101 in Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allecra</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Allecra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2, randomised, double-blind, 2-cohort study in hospitalised adults with complicated
      urinary tract infection (cUTI), including acute pyelonephritis. All study cohorts were
      randomised in a 2:1 ratio. Treatment duration for each cohort was 7 to 10 days. Patients were
      not permitted to switch to oral therapy.

      Cohort 1: 15 patients treated with cefepime 1 g/AAI101 500 mg intravenous (i.v.) infusion
      over 2 hours once every 8 hours (q8h), and 7 patients treated with cefepime 1 g i.v. infusion
      over 2 hours q8h.

      Cohort 2: 15 patients treated with cefepime 2 g/AAI101 750 mg i.v. infusion over 2 hours q8h,
      and 8 patients treated with cefepime 2 g i.v. infusion over 2 hours q8h.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 5, 2017</start_date>
  <completion_date type="Actual">February 14, 2018</completion_date>
  <primary_completion_date type="Actual">February 14, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-Treat (mMITT) Population</measure>
    <time_frame>6 to 9 days post-End of Treatment</time_frame>
    <description>Microbiological response is eradication for each baseline pathogen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiological Response at the TOC Visit in the Microbiologically Evaluable (ME) Population.</measure>
    <time_frame>6 to 9 days post-End of Treatment</time_frame>
    <description>Microbiological response is eradication for each baseline pathogen</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Cefepime 1G - 2G / AAI101 0.5G - 0.75G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cefepime 1 g or cefepime 2 g in combination with AAI101 500 mg or 750 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cefepime monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cefepime 1 g or cefepime 2 g</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefepime 1G - 2G / AAI101 0.5G - 0.75G</intervention_name>
    <description>Experimental drug</description>
    <arm_group_label>Cefepime 1G - 2G / AAI101 0.5G - 0.75G</arm_group_label>
    <other_name>cefepime/AAI101 combination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefepime 1 g or cefepime 2 g</intervention_name>
    <description>cefepime monotherapy</description>
    <arm_group_label>cefepime monotherapy</arm_group_label>
    <other_name>cefepime alone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        • Male or female patients with clinical signs and/or symptoms of cUTI or acute
        pyelonephritis that were expected to require hospitalization and initial treatment with at
        least 7 days of i.v.

        antibiotics.

        Exclusion criteria:

          -  Patients with concurrent infection that would interfere with evaluation of response to
             the study antibiotics;

          -  Patients needing concomitant systemic antimicrobial agents in addition to those
             designated in the various study treatment groups;

          -  Patients receiving effective antibacterial drug therapy for any indication for a
             continuous duration of &gt;24 hours during the previous 72 hours before the
             study-qualifying baseline urine was obtained or receiving any amount of potentially
             therapeutic antibacterial therapy after collection of the pre-treatment baseline urine
             culture and before administration of the first dose of study drug;

          -  Patients likely to require the use of an antibiotic for cUTI or acute pyelonephritis
             prophylaxis during participation in the study;

          -  Patients with confirmed fungal urinary tract infection at the screening visit (with
             ≥103 fungal colony forming units [CFU]/mL); or

          -  Patients with intractable urinary infection at baseline that the Investigator
             anticipated would require &gt;10 days of study drug therapy were excluded from
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kromerizska nemocnice</name>
      <address>
        <city>Kromeriz</city>
        <zip>76701</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jahn Ferenc Del-pesti Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1204</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji w Warszawie, Klinika Chorob Wewnetrznych, Nefrologii i Transplantologii</name>
      <address>
        <city>Warsaw</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultna nemocnica s poliklinikou J.A. Reimana Presov</name>
      <address>
        <city>Prešov</city>
        <zip>081 81</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chernihiv City Hospital #2 of Chernihiv City Council, department of Urology</name>
      <address>
        <city>Chernihiv</city>
        <zip>14034</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 19, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>September 20, 2018</last_update_submitted>
  <last_update_submitted_qc>September 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefepime</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

